Leap Therapeutics, Inc. (LPTX) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
LPTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
LPTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | 100.0% | -2761.7% | -2705.8% |
Download Data
Export LPTX earnings history in CSV or JSON format
Free sign-in required to download data
Leap Therapeutics, Inc. (LPTX) Earnings Overview
As of May 8, 2026, Leap Therapeutics, Inc. (LPTX) reported trailing twelve-month net income of $15M, reflecting +103.9% year-over-year growth. The company earned $0.22 per diluted share over the past four quarters.
Looking at the long-term picture, LPTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $15M in fiscal 2025, representing a new all-time high.
Leap Therapeutics, Inc. maintains positive profitability with. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including IMVT (-$464M net income), AGEN ($115,000 net income, 0.1% margin), TGTX ($462M net income, 72.6% margin), LPTX has comparable earnings metrics. Compare LPTX vs IMVT →
LPTX Earnings vs Peers
Earnings metrics vs comparable public companies
LPTX Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $15M | +122.7% | -$41M | $0.07 | - | - |
| 2024 | -$68M | +17.0% | -$70M | $-1.81 | - | - |
| 2023 | -$81M | -49.1% | -$87M | $-3.98 | - | - |
| 2022 | -$55M | -34.5% | -$57M | $-4.82 | - | - |
| 2021 | -$41M | -1098.3% | -$41M | $-4.73 | -2705.8% | -2761.7% |
| 2020 | -$3M | +1.7% | -$3M | $-4.64 | -33.7% | -34.3% |
| 2019 | -$3M | +85.1% | -$3M | $-14.57 | -35.6% | -35.9% |
| 2018 | -$23M | +22.2% | -$31M | $-16.05 | - | - |
| 2017 | -$30M | -16.0% | -$32M | $-32.35 | - | - |
| 2016 | -$26M | -21.5% | -$28M | $-27.29 | - | - |
See LPTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LPTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LPTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLPTX — Frequently Asked Questions
Quick answers to the most common questions about buying LPTX stock.
Is LPTX growing earnings?
LPTX EPS is $0.22, with earnings growth accelerating to +103.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $15M.
What are LPTX's profit margins?
Leap Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are LPTX's earnings?
LPTX earnings data spans 2012-2025. The accelerating earnings trend is +103.9% YoY. Historical data enables comparison across business cycles.